You Are Not Alone: Call the National Suicide Hotline’s Veterans Crisis Line at 988 (Press 1), Chat Live or Text 838255 for 24/7 Confidential Crisis Support for Veterans and Their Loved Ones
Read Press ReleaseAmerican Heart Association CPR Certification School Opens in Oakland, California. This School Will Provide CPR, BLS, ACLS, PALS, and First-Aid Certification Courses to the Residents of Alameda County.
Read Press ReleaseFlorence Healthcare, the leading provider of Site Enablement Platforms for clinical trials, announced today that it has acquired VersaTrial, a cutting-edge clinical trial solutions provider.
Read Press ReleaseVibrant Wellness introduces the Toxin Genetics Test, a cutting-edge addition to its suite of advanced functional lab tests. This revolutionary tool assesses genetic biomarkers pivotal to the body's detox process, aiding healthcare professionals in designing individualized detoxification plans.
Read Press ReleaseThe Oct. 2-3 hybrid workshop will bridge the gap between critical stakeholders to pinpoint today's challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.
Read Press ReleaseLeadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran
Total venture funding tops $50M to date
HealthAxis, a prominent provider of core administrative processing solutions and BPaaS capabilities to healthcare payers, risk-bearing providers, and third-party administrators, announced it has been Certified™ by Great Place to Work®, the foremost authority on workplace culture, employee experience, and the leadership qualities essential for driving market-leading revenue, employee retention, and innovation.
Read Press ReleaseThe health IT vendor partnership extends Interlace Health's forms automation and electronic signature capture capabilities to MEDITECH Expanse EHR customers
Read Press ReleaseAmelia™-1 Study is testing if evexomostat can improve patients' safety and clinical response to a PI3K inhibitor plus an estrogen receptor degrader. Evexomostat, a novel MetAP2 inhibitor, controlled PI3K-induced hyperglycemia in the first study patient, consistent with pre-clinical data. Further, ctDNA data shows no evidence of residual PIK3CA mutation in blood after 6 weeks of treatment.
Read Press ReleaseGenerative Artificial Intelligence Solution Unlocks Proprietary Data to Support Perioperative Leaders' Ability to Optimize OR Utilization and Dramatically Increase OR Margin
Read Press ReleaseUnveiling the Potential Breakthrough - Activating Stem Cells to Delay and Reduce Dementia and Depression Risk
Read Press Release